Logo.jpg
Endonovo Therapeutics Provides Corporate Update
April 26, 2019 08:00 ET | Endonovo Therapeutics, Inc.
LOS ANGELES, CA, April 26, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapeutic...
ARC logo.png
Cardiovascular and Soft Tissue Repair Patches Market Size Worth Around US$ 6 billion by 2026: Acumen Research and Consulting
April 18, 2019 11:00 ET | Acumen Research and Consulting
LOS ANGELES, April 18, 2019 (GLOBE NEWSWIRE) -- The global Cardiovascular and Soft Tissue Repair Patches Market is forecasted to grow at a stable CAGR around 8% during the forecast period and reach...
RVX_logo_RGB.jpg
Resverlogix’ BETonMACE Phase 3 Trial Successfully Reaches its Targeted 250 MACE Events
April 18, 2019 08:00 ET | Resverlogix Corp
CALGARY, Alberta, April 18, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) today announces that BETonMACE, the Company’s event-based, phase 3 registration...
15-SORRENTO-Therapeutics-Logo-FINAL.png
Sorrento Therapeutics Expands Resiniferatoxin (RTX) Clinical Development Program to Life-Threatening Cardiovascular Diseases With Completion of Major Animal Toxicology Study
April 15, 2019 04:00 ET | Sorrento Therapeutics, Inc.
SAN DIEGO, April 15, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that its Neuro-Therapeutics unit is pursuing clinical development of resiniferatoxin...
InCarda Logo.png
InCarda Therapeutics Appoints Daniel G. Welch as Executive Chairman of Board of Directors
April 03, 2019 08:00 ET | InCarda Therapeutics, Inc.
SAN FRANCISCO, April 03, 2019 (GLOBE NEWSWIRE) -- InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for...
RVX_logo_RGB.jpg
Resverlogix Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial Presented at the International Conference on Alzheimer’s & Parkinson’s Diseases
April 01, 2019 11:00 ET | Resverlogix Corp
CALGARY, Alberta, April 01, 2019 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX) today announces that Dr. Jeffrey Cummings, Founding Director of the Cleveland Clinic...
ARCA Logo - JPEG.jpg
Identification of Phosphodiesterease 3A Polymorphism With Potential to Increase Effectiveness of PDE3 Inhibitors Published in the Journal of the American College of Cardiology
March 18, 2019 08:30 ET | ARCA biopharma, Inc.
WESTMINSTER, Colo., March 18, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA Logo - JPEG.jpg
Dose Response of Beta-Blockers in Adrenergic Receptor Polymorphism Genotypes Paper Published in Circulation: Genomic and Precision Medicine
March 06, 2019 08:00 ET | ARCA biopharma, Inc.
WESTMINSTER, Colo., March 06, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA Biopharma Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support Approval for the First Genetically-Targeted Cardiovascular Drug
February 20, 2019 07:30 ET | ARCA biopharma, Inc.
FDA Special Protocol Assessment agreement granted for PRECISION-AF clinical trial evaluating Gencaro as a potential treatment for atrial fibrillation in a heart failure population that has no FDA...
InCarda Logo.png
New Patent Issuances Strengthen InCarda Therapeutics’ Intellectual Property Portfolio Covering Novel Inhaled Cardiovascular Therapies
February 07, 2019 08:05 ET | InCarda Therapeutics, Inc.
U.S. Patent Broadly Expands Coverage for Inhaled Treatment of Cardiovascular Disease to Include all Class I – IV Antiarrhythmic Drugs Additional U.S. Patent Provides Coverage for Combination of...